Currently, accepted clinical methods to diagnose clinically significant prostate cancer (PCa) are a combination of the prostate-specific antigen (PSA) test, digital rectal exam, trans-rectal ultrasound (TRUS), and magnetic resonance imaging (MRI). Here, KLK3 is linked to prostate cancer.